We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Pancreatic Cancer
MedXY News
EnglishTag

Pancreatic Cancer

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Unveiling Hidden High-Risk Phenotypes in Resected Solid Pseudopapillary Tumors Using Anomaly-Detection Models
General Surgerysurvival analysisanomaly detection

Unveiling Hidden High-Risk Phenotypes in Resected Solid Pseudopapillary Tumors Using Anomaly-Detection Models

By MedXY|Sep 15, 2026

This study employs interpretable anomaly-detection algorithms to identify high-risk phenotypes in resected solid pseudopapillary pancreatic tumors, overcoming limitations of conventional survival models in ultra-rare cancer-specific deaths.

Circulating Exosomal microRNA Signature Enhances Preoperative Detection of Occult Liver Metastases in Pancreatic Cancer
General SurgeryExosomal microRNA
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Liver Metastasis

Circulating Exosomal microRNA Signature Enhances Preoperative Detection of Occult Liver Metastases in Pancreatic Cancer

By MedXY|Sep 7, 2026

A multicenter study developed a robust exosomal microRNA-based model enabling preoperative detection of occult liver micrometastasis in pancreatic ductal adenocarcinoma, improving risk stratification and guiding treatment sequencing.

Targeting the CA19-9 Glycan: A Promising CAR T Cell Therapy for Pancreatic and Gastrointestinal Cancers
GastroenterologyCA19-9CAR T-cell therapy

Targeting the CA19-9 Glycan: A Promising CAR T Cell Therapy for Pancreatic and Gastrointestinal Cancers

By MedXY|Aug 29, 2026

CAR T cells targeting the CA19-9 glycan show potent, specific anti-tumor activity in pancreatic and various gastrointestinal cancers, providing new avenues for immunotherapy of hard-to-treat solid tumors.

Nationwide Evaluation of Robotic Distal Pancreatectomy for Malignancy: Safety, Outcomes, and Comparative Effectiveness in Japan
General SurgeryPhẫu thuật xâm lấn tối thiểurobotic distal pancreatectomy

Nationwide Evaluation of Robotic Distal Pancreatectomy for Malignancy: Safety, Outcomes, and Comparative Effectiveness in Japan

By MedXY|Aug 12, 2026

This study analyzes nationwide data from Japan comparing robotic, laparoscopic, and open distal pancreatectomy for malignancy, highlighting robotic surgery’s safety and specific perioperative advantages, notably reduced blood loss and conve

Targeting the IL-17/NGAL/NETs/ITGA5 Axis: A Novel Strategy to Overcome Immunosuppression and Fibroblast Reprogramming in Pancreatic Cancer
Gastroenterologycancer-associated fibroblastsimmunosuppression

Targeting the IL-17/NGAL/NETs/ITGA5 Axis: A Novel Strategy to Overcome Immunosuppression and Fibroblast Reprogramming in Pancreatic Cancer

By MedXY|Jul 20, 2026

This study unravels how tumour-derived NGAL induces NETs that reprogram fibroblast subtypes via ITGA5, promoting immunosuppression and tumour progression in pancreatic ductal adenocarcinoma, suggesting combinatorial therapies to enhance imm

Multimodal C9-66 CAR-T Cell Therapy: A Promising Advance in Pancreatic Cancer Treatment
newsCAR-T Therapyimmunotherapy

Multimodal C9-66 CAR-T Cell Therapy: A Promising Advance in Pancreatic Cancer Treatment

By MedXY|Jul 16, 2026

This article reviews the development and preclinical evaluation of C9-66 CAR-T cell therapy targeting oncofetal chondroitin sulfate in pancreatic cancer, highlighting metabolic and microenvironmental optimizations that improve efficacy and

Fibrosis-Driven Activation of Schwann Cells in Pancreatic Cancer: Unraveling the Nuclear Mechanosensing Pathway
GastroenterologyfibrosisMechanosensing

Fibrosis-Driven Activation of Schwann Cells in Pancreatic Cancer: Unraveling the Nuclear Mechanosensing Pathway

By MedXY|Jun 25, 2026

Pancreatic fibrosis activates Schwann cells via nuclear mechanosensing, promoting a protumorigenic environment that enhances pancreatic cancer progression, offering novel microenvironment-targeted therapeutic insights.

Pancreatic Cancer Risk During IPMN Surveillance: A SEER-Based Comparison
GastroenterologyIPMNPancreatic Cancer

Pancreatic Cancer Risk During IPMN Surveillance: A SEER-Based Comparison

By MedXY|Jun 1, 2026

A SEER-based study found IPMN surveillance patients have about 10 times higher pancreatic cancer risk than the general population, with highest risk in those with main duct dilation or obesity.

Targeting Oncomucin-Driven Immunosuppression Improves KRAS G12D Inhibition in Pancreatic Cancer
Gastroenterologyimmune suppressionKRAS G12D

Targeting Oncomucin-Driven Immunosuppression Improves KRAS G12D Inhibition in Pancreatic Cancer

By MedXY|May 28, 2026

Oncomucins such as MUC4 and MUC16 help pancreatic cancer evade immunity through EGFR/UNC5B signaling. Targeting these mucins may enhance KRAS G12D inhibitor efficacy and reduce tumor burden.

KRAS-Driven CLDN18.2 O-GlcNAcylation Promotes Pancreatic Cancer Progression and Therapy Resistance
GastroenterologyCLDN18.2KRAS mutation

KRAS-Driven CLDN18.2 O-GlcNAcylation Promotes Pancreatic Cancer Progression and Therapy Resistance

By MedXY|May 16, 2026

KRAS mutation and high glucose promote O-GlcNAcylation of CLDN18.2 in pancreatic cancer, pushing the protein off the cell membrane, boosting metastasis, and weakening CLDN18.2-targeted therapy. Low-dose MRTX1133 may restore sensitivity.

Age-Dependent Interplay of Modifiable Risk Factors and Genetic Risk in Pancreatic Cancer
newsgenetic risklifestyle risk factors

Age-Dependent Interplay of Modifiable Risk Factors and Genetic Risk in Pancreatic Cancer

By MedXY|May 15, 2026

A UK Biobank study found that lifestyle-related pancreatic cancer risks were strongest in younger adults, especially those with high genetic risk, supporting early prevention efforts.

CD276 Identified as Key Driver of Chemoresistance in Advanced Pancreatic Cancer
GastroenterologyCD276Pancreatic Cancer

CD276 Identified as Key Driver of Chemoresistance in Advanced Pancreatic Cancer

By MedXY|Apr 29, 2026

Single-cell analysis reveals CD276/B7-H3 as a critical regulator of chemoresistance in pancreatic ductal adenocarcinoma, highlighting its dual role in promoting basal-like tumor states and immune evasion.

New EHR-Based Model PRIME Achieves 0.75 AUC in Predicting Pancreatic Cancer Risk Across 11 Million Patients
Gastroenterologyearly detectionEHR

New EHR-Based Model PRIME Achieves 0.75 AUC in Predicting Pancreatic Cancer Risk Across 11 Million Patients

By MedXY|Apr 6, 2026

Researchers developed PRIME, a parsimonious risk stratification model for pancreatic ductal adenocarcinoma using electronic health record data. Validated across US health systems and the UK Biobank, PRIME retained 19 predictors and achieved

Beyond Pathology: DNA/RNA Sequencing Achieves Near-Double Sensitivity in Detecting Bile Duct Cancer
Gastroenterologybile duct stricturesCholangiocarcinoma

Beyond Pathology: DNA/RNA Sequencing Achieves Near-Double Sensitivity in Detecting Bile Duct Cancer

By MedXY|Apr 2, 2026

A landmark six-year study involving over 2,000 patients at 28 institutions demonstrates that next-generation sequencing of ERCP-obtained specimens achieves 82% sensitivity for neoplastic bile duct strictures, nearly doubling traditional pat

Redefining Success in Neoadjuvant Therapy for Pancreatic Cancer: The Prognostic Significance of Major Pathologic Response
Clinical Updatesneoadjuvant therapyPancreatic Cancer

Redefining Success in Neoadjuvant Therapy for Pancreatic Cancer: The Prognostic Significance of Major Pathologic Response

By MedXY|Mar 28, 2026

This review evaluates the prognostic value of Major Pathologic Response (MPR) in pancreatic ductal adenocarcinoma, analyzing its impact on survival and its potential to guide personalized adjuvant treatment strategies.

Precision Nutrition, Neoadjuvant Oncology, and Prehospital Analgesia: Key Clinical Milestones from the 2025 Lancet Series
Clinical UpdatesEAT‑LancetNutritional Science

Precision Nutrition, Neoadjuvant Oncology, and Prehospital Analgesia: Key Clinical Milestones from the 2025 Lancet Series

By MedXY|Mar 20, 2026

This review synthesizes landmark clinical evidence regarding the nutritional adequacy of the EAT-Lancet diet, the superiority of PAXG chemotherapy in pancreatic cancer, and the efficacy of methoxyflurane for prehospital acute pain managemen

The Socio-Clinical Impact of Medicaid Expansion on Pancreatic Cancer Survival: Evidence from a Multi-State Longitudinal Analysis
Clinical UpdatesMở rộng MedicaidPancreatic Cancer

The Socio-Clinical Impact of Medicaid Expansion on Pancreatic Cancer Survival: Evidence from a Multi-State Longitudinal Analysis

By MedXY|Mar 20, 2026

This review synthesizes findings on how Medicaid expansion timing influenced surgical resection rates and 2-year mortality for pancreatic cancer, revealing significant survival benefits alongside persistent socioeconomic disparities.

PAXG Challenges mFOLFIRINOX as the New Standard for Preoperative Pancreatic Cancer Care: Insights from the CASSANDRA Trial
Gastroenterologyneoadjuvant therapyPancreatic Cancer

PAXG Challenges mFOLFIRINOX as the New Standard for Preoperative Pancreatic Cancer Care: Insights from the CASSANDRA Trial

By MedXY|Mar 2, 2026

The Phase 3 CASSANDRA trial reveals that the four-drug PAXG regimen significantly improves event-free survival compared to mFOLFIRINOX in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma, potentially redefi

New-Onset Diabetes as a Sentinel for Pancreatic Cancer: Racial Disparities and the Critical Three-Year Window
Diabetes & Endocrinologynew-onset diabetesoncology

New-Onset Diabetes as a Sentinel for Pancreatic Cancer: Racial Disparities and the Critical Three-Year Window

By MedXY|Feb 4, 2026

A prospective study of 18,838 adults reveals that glycemically defined new-onset diabetes (GNOD) significantly increases the 3-year risk of pancreatic cancer, with notable racial variations and a critical 8-month diagnostic window.

THAG Regimen Shows High Efficacy as Conversion Therapy for Pancreatic Cancer: New Phase II Trial Results
Gastroenterologyimmunotherapyneoadjuvant therapy

THAG Regimen Shows High Efficacy as Conversion Therapy for Pancreatic Cancer: New Phase II Trial Results

By MedXY|Jan 13, 2026

A Phase II trial demonstrates that the THAG regimen—combining immunotherapy, radiotherapy, and chemotherapy—significantly improves R0 resection rates and survival in patients with BRPC and LAPC, supported by IL-6 and ctDNA biomarker insight

1 / 2
12
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities